Oncolytic viruses: have solid tumors met their match?

#Tumor #OncolyticVirus #Oncology #NewTherapy    


Intermediate to advanced-stage solid tumors represent a major therapeutic challenge. Their limited response to conventional treatments—surgery, chemotherapy, radiotherapy—has created a pressing need for innovative approaches. Among these, oncolytic viruses (OVs) are emerging as a promising option. Capable of selectively infecting and destroying tumor cells while stimulating an antitumor immune response, these viruses are being tested across numerous cancer types. However, their actual effectiveness in humans remains to be clarified, particularly in terms of survival and objective response. In this context, this study was initiated to systematically and quantitatively evaluate the clinical efficacy of oncolytic viruses in the treatment of intermediate to advanced solid tumors, by analyzing the results of available clinical trials.